Czechia· CZ-0223080

NERLYNX

A neratinib product containing neratinib maleate, registered in Czechia by PIERRE FABRE MEDICAMENT, Lavaur. The same ATC class is registered in 13 of our 19 countries.

ATC L01EH02

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedNERLYNXATCL01EH02REGISTER NO.CZ-0223080PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Neratinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L01EH02 (neratinib), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 8 of them publish a price we can compare per daily dose

Neratinib · ATC L01EH02

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

SÚKL (Czech Republic)
Active substance
NERATINIB MALEATE
Manufacturer
PIERRE FABRE MEDICAMENT, Lavaur
Country
Czechia (CZ)
ATC code
L01EH02
ATC class
Neratinib
Defined daily dose
0.24 g, O
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 1

1 priced
  • cz_kod_sukl
    0223080
    180
    CZK 96633.8

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

226 interactions on record for neratinib.

Graded by severity as the source publishes them — 97 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Neratinib · interactions on record

226 records

  • 97 severe
  • 123 moderate
  • 6 minor

Most severe, free to view

  • ClotrimazoleA01AB18severe
  • CimetidineA02BA01severe
  • RanitidineA02BA02severe
  • FamotidineA02BA03severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Neratinib in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All neratinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Nerlynx
  • Liechtenstein · Nerlynx
  • Norway · Nerlynx

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ed8e588d-692a-4eb8-bc7e-04fa4324b911
GET /v1/drugs/ed8e588d-692a-4eb8-bc7e-04fa4324b911?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "TBL FLM",
  "source": "sukl",
  "strength": "40MG",
  "pack_size": "180",
  "substance": "NERATINIB MALEATE",
  "cz_kod_sukl": "0223080",
  "product_type": "CH",
  "substance_codes": "21452",
  "registration_state": "R",
  "registration_number": "EU/1/18/1311/001"
}

See everything about neratinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.